B · Normal
[East Asia Pharmaceuticals: Trimebutine Maleate Tablets Obtained Drug Registration Certificate] On November 17, East Asia Pharmaceutical (605177.SH) announced that the company received the "Drug Registration Certificate" for trimebutine maleate tablets approved and issued by the State Food and Drug Administration. The dosage form is tablets, specifications 0.2g and 0.1g, and the registration classification is Class 3 chemical drugs. This medicine can be used to relieve gastrointestinal discomforts such as bloating, abdominal pain, and hiccups caused by chronic gastritis, and to treat irritable bowel syndrome. Relevant data shows that the sales of trimebutine maleate tablets in medical institutions and physical pharmacies nationwide in 2025 will be approximately 280 million yuan. The company stated that obtaining the drug registration certificate this time will further enrich the preparation product line and promote the implementation of the integration strategy of raw materials and preparations.
A-share announcement express 🕐 2026-11-17 15:34

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet